Table 1.
Patient baseline clinical characteristics.
| Clinical characteristics of the study population | |
|---|---|
| Number | 187 |
| Age (years) | 65 ± 13 |
| Males (%) | 78 |
| Ischemic cardiomyopathy (%) | 40 |
| Diabetes mellitus (%) | 25 |
| Arterial hypertension (%) | 61 |
| NYHA class | 2.3 ± 0.6 |
| Body mass index (kg/m2) | 28 ± 5 |
| Systolic arterial pressure (mm Hg) | 119 ± 15 |
| Diastolic arterial pressure (mm Hg) | 69 ± 9 |
| Heart rate (b/min) | 70 ± 11 |
| Atrial fibrillation (%) | 21 |
| GFR-EPI (ml/min/1.73 m2) | 69 ± 24 |
| NT-proBNP (pg/ml) | 1277 ± 1473 |
| LVEF (%) | 34 ± 9 |
| MR (a.u.) | 1.6 ± 1.1 |
| TR (a.u.) | 1.5 ± 0.9 |
| TAPSE (mm) | 19 ± 4 |
| PASP (mm Hg) | 35 ± 10 |
| CVP > 5 mm Hg (%) | 16 |
| Concomitant therapy (%) | |
| ACE-inhibitors and/or ARBs | 90 |
| Beta-blockers | 97 |
| Loop diuretics | 100 |
| Aldosterone antagonists | 66 |
CVP: central venous pressure. GFR-EPI: glomerular filtration rate by CKD-EPI formula; LVEF: left ventricular ejection fraction; MR: mitral regurgitation; NT-proBNP: N-terminal pro-brain natriuretic peptide; PASP: systolic peak of pulmonary arterial pressure; TAPSE: peak of tricuspid annular plane systolic excursion; TR: tricuspid regurgitation.